4.7 Article

Mislocated FUS is sufficient for gain-of-toxic-function amyotrophic lateral sclerosis phenotypes in mice

期刊

BRAIN
卷 139, 期 -, 页码 2380-2394

出版社

OXFORD UNIV PRESS
DOI: 10.1093/brain/aww161

关键词

TDP-43; amyotrophic lateral sclerosis; frontotemporal lobar degeneration; protein aggregation; RNA processing

资金

  1. Eisai Co. Ltd.
  2. Foundation of Japan Amyotrophic Lateral Sclerosis Association
  3. Novartis Pharma
  4. Brain Science Foundation
  5. Life Science Foundation of Japan
  6. Ministry of Education, Culture, Sports, Science and Technology of Japan [15K09323]
  7. Nakabayashi Trust for ALS Research
  8. Kaken Grants-in-AID for Scientific Research [24890228]
  9. Grants-in-Aid for Scientific Research [16J05812, 24890228, 15K09323] Funding Source: KAKEN

向作者/读者索取更多资源

Mutations in RNA-binding proteins, including fused in sarcoma (FUS) and TAR DNA-binding protein 43 (TDP-43, encoded by TARDBP), are associated with sporadic and familial amyotrophic lateral sclerosis. A major question is whether neuronal loss is caused by toxic gain-of-function cytoplasmic aggregates or loss of nuclear RNA-binding protein function. We generated a transgenic mouse overexpressing exogenous FUS without a nuclear localization signal (Delta NLS-FUS), which developed progressive spastic motor deficits and neuronal loss in the motor cortex. The Delta NLS-FUS protein was restricted to the cytoplasm and formed ubiquitin/p62-positive aggregates. Endogenous FUS expression, nuclear localization, and splicing activity were not altered, indicating that mislocated FUS is sufficient for proteinopathy. Crossing Delta NLS-FUS with wild-type human TDP-43 transgenic mice exacerbated pathological and behavioural phenotypes, suggesting that both proteins are involved in a common cascade. RNA-sequence analysis revealed specific transcriptome alterations, including genes regulating dynein-associated molecules and endoplasmic reticulum stress. Delta NLS-FUS mice are promising tools for understanding amyotrophic lateral sclerosis pathogenesis and testing new therapeutic approaches.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据